Comparing two types of macrolide antibiotics for the purpose of assessing Population-based drug interactions

BMJ Open

Volumn 3, Issue 7, 2013, Pages

  Fleet, Jamie L ^a   Shariff, Salimah Z ^a,b   Bailey, David G ^c   Gandhi, Sonja ^a   Juurlink, David N ^b,d,e   Nash, Danielle M ^a,b   Mamdani, Muhammad ^b,e   Gomes, Tara ^b   Patel, Amit M ^a   Garg, Amit X ^a,b  

^a UNIVERSITY OF WESTERN ONTARIO   (Canada)

^b INSTITUTE FOR CLINICAL EVALUATIVE SCIENCES   (Canada)

^c LONDON HEALTH SCIENCES CENTRE   (Canada)

^d UNIVERSITY OF TORONTO   (Canada)

^e UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AZITHROMYCIN; CLARITHROMYCIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENZYME; ERYTHROMYCIN; LOOP DIURETIC AGENT; MACROLIDE; NONSTEROID ANTIINFLAMMATORY AGENT; POTASSIUM SPARING DIURETIC AGENT; PRESCRIPTION DRUG; THIAZIDE DIURETIC AGENT;

ACUTE HEART INFARCTION; ARTICLE; BRAIN ISCHEMIA; COMPARATIVE STUDY; DRUG BLOOD LEVEL; DRUG INTERACTION; DRUG METABOLISM; DRUG TRANSPORT; DRUG USE; FAINTNESS; FOLLOW UP; GASTROINTESTINAL HEMORRHAGE; HEART ARRHYTHMIA; HOSPITAL ADMISSION; HUMAN; HYPERGLYCEMIA; HYPERKALEMIA; HYPONATREMIA; HYPOTENSION; INFECTION; KIDNEY FAILURE; KIDNEY INJURY; MORTALITY; NEUROIMAGING; PHYSICIAN; POPULATION BASED CASE CONTROL STUDY; PRESCRIPTION; TREATMENT OUTCOME;

EID: 84880580308     PISSN: None     EISSN: 20446055     Source Type: Journal    
DOI: 10.1136/bmjopen-2013-002857     Document Type: Article

References (39)

1. Dresser GK, Spence JD, Bailey DG. Pharmacokineticpharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition. Clin Pharmacokinet 2000;38:41-57. (Pubitemid 30055093)
2. Wilkinson GR. Drug metabolism and variability among patients in drug response N Engl J Med 2005;352:2211-21.
3. Bailey DG, Dresser G, Arnold JM. Grapefruit-medication interactions: forbidden fruit or avoidable consequences? CMAJ 2013;185:309-16.
4. Hutson JR, Fischer HD, Wang X, et al. Use of clarithromycin and adverse cardiovascular events among older patients receiving donepezil: a population-based, nested case-control study. Drugs Aging 2012;29:205-11.
5. Neuvonen PJ, Niemi M, Backman JT. Drug interactions with lipid-lowering drugs: mechanisms and clinical relevance Clin Pharmacol Ther 2006;80:565-81. (Pubitemid 44908269)
6. Pauwels O. Factors contributing to carbamazepine-macrolide interactions Pharmacol Res 2002;45:291-8.
7. Seithel A, Eberl S, Singer K, et al. The influence of macrolide antibiotics on the uptake of organic anions and drugs mediated by OATP1B1 and OATP1B3. Drug Metab Dispos 2007;35:779-86. (Pubitemid 46641549)
8. Westphal JF. Macrolide-induced clinically relevant drug interactions with cytochrome P-450A (CYP) 3A4: an update focused on clarithromycin, azithromycin and dirithromycin. Br J Clin Pharmacol 2000;50:285-95.
9. Polasek TM, Miners JO. Quantitative prediction of macrolide drug-drug interaction potential from in vitro studies using testosterone as the human cytochrome P4503A substrate. Eur J Clin Pharmacol 2006;62:203-8. (Pubitemid 43357578)
10. Patel AM, Shariff S, Bailey DG, et al. Statin toxicity from macrolide antibiotic co-prescription: a population based study of older adults. Ann Intern Med 2013;158:869-76.
11. Clarithromycin Drug Information. Upto Date online V 20.3. 2012. 5-25-0120. Ref Type: Electronic Citation
12. Azithromycin Drug Information. Upto Date online V 20.3. 2012. 5-25-0120. Ref Type: Electronic Citation
13. McKinnell J, Tayek JA. Short term treatment with clarithromycin resulting in colchicine-induced rhabdomyolysis J Clin Rheumatol 2009;15:303-5.
14. Pasqualetti G, Bini G, Tognini S, et al. Clarithromycin-induced rhabdomyolysis: a case report Int J Gen Med 2012;5:283-5.
15. Wright AJ, Gomes T, Mamdani MM, et al. The risk of hypotension following co-prescription of macrolide antibiotics and calciumchannel blockers. Cmaj 2011;183:303-7.
16. Statistics Canada. Population by sex and age group, by province and territory. Ottawa: Statistics Canada, 2011;8-10-0120. Ref Type: Electronic Citation
17. von EE, Altman DG, Egger M, et al. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Ann Intern Med 2007;147:573-7. (Pubitemid 351664504)
18. Levy AR, O'Brien BJ, Sellors C, et al. Coding accuracy of administrative drug claims in the Ontario Drug Benefit database Can J Clin Pharmacol 2003;10:67-71. (Pubitemid 37028596)
19. Jain AK, Cuerden MS, McLeod I, et al. Reporting of the estimated glomerular filtration rate was associated with increased use of angiotensin-converting enzyme inhibitors and angiotensin-II receptor blockers in CKD. Kidney Int 2012;81:1248-53.
20. Shih AW, Weir MA, Clemens KK, et al. Oral bisphosphonate use in the elderly is not associated with acute kidney injury Kidney Int 2012;82:903-8.
21. Zhao YY, Weir MA, Manno M, et al. New fibrate use and acute renal outcomes in elderly adults: a population-based study Ann Intern Med 2012;156:560-9.
22. Flockhart DA. Drug interactions: cytochrome P450 drug interaction table India. 2012. Ref Type: Electronic Citation
23. Niemi M, Pasanen MK, Neuvonen PJ. Organic anion transporting polypeptide 1B1: a genetically polymorphic transporter of major importance for hepatic drug uptake. Pharmacol Rev 2011;63:157-81.
24. Calcium channel blockers+macrolides: elderly patients hospitalised for low blood pressure. Prescrlre Int 2012;21:182.
25. Bode C. The nasty surprise of a complex drug-drug interaction Drug Discov Today 2010;15:391-5.
26. Lee CY, Marcotte F, Giraldeau G, et al. Digoxin toxicity precipitated by clarithromycin use: case presentation and concise review of the literature. Can J Cardiol 2011;27:870-6.
27. Trieu J, Emmett L, Perera C, et al. Rhabdomyolysis resulting from interaction of simvastatin and clarithromycin demonstrated by Tc-99m MDP scintigraphy. Clin Nucl Med 2004;29:803-4. (Pubitemid 39557554)
28. Kute VB, Shah PR, Goplani KR, et al. Successful treatment of refractory hypotension, noncardiogenic pulmonary edema and acute kidney injury after an overdose of amlodipine. Indian J Crit Care Med 2011;15:182-4.
29. Austin PC. Using the standardized difference to compare the prevalence of a binary variable between two groups in observational research. Commun Stat Simulation Comput 2009;38:1228-34.
30. Mamdani M, Sykora K, Li P, et al. Reader's guide to critical appraisal of cohort studies: 2. Assessing potential for confounding. BMJ 2005;330:960-2. (Pubitemid 40592320)
31. Charlson ME, Pompei P, Ales KL, et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987;40:373-83. (Pubitemid 17055592)
32. Kanatani MS, Guglielmo BJ. The new macrolides. Azithromycin and clarithromycin. West J Med 1994;160:31-7.
33. Davey PG. The pharmacokinetics of clarithromycin and its 14-OH metabolite J Hosp Infect 1991;19(Suppl A):29-37.
34. Bland JM, Altman DG. Statistical methods for assessing agreement between two methods of clinical measurement Lancet 1986;1:307-10. (Pubitemid 16134762)
35. Ray WA, Murray KT, Meredith S, et al. Oral erythromycin and the risk of sudden death from cardiac causes N Engl J Med 2004;351:1089-96.
36. Ray WA, Murray KT, Hall K, et al. Azithromycin and the risk of cardiovascular death N Engl J Med 2012;366:1881-90.
37. Zambon A, Polo FH, Contiero P, et al. Effect of macrolide and fluoroquinolone antibacterials on the risk of ventricular arrhythmia and cardiac arrest: an observational study in Italy using case-control, case-crossover and case-time-control designs. Drug Saf 2009;32:159-67.
38. Bradbury F. Comparison of azithromycin versus clarithromycin in the treatment of patients with lower respiratory tract infection. J Antimicrob Chemother 1993;31(Suppl E):153-62. (Pubitemid 23220200)
39. Muller O. Comparison of azithromycin versus clarithromycin in the treatment of patients with upper respiratory tract infections. J Antimicrob Chemother 1993;31(Suppl E):137-46. (Pubitemid 23220198)